TALIMOGENE LAHERPAREPVEC for Off label use: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 35 adverse event reports in the FDA FAERS database where TALIMOGENE LAHERPAREPVEC was used for Off label use.
Most Reported Side Effects for TALIMOGENE LAHERPAREPVEC
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 196 | 13.3% | 25 | 25 |
| Pyrexia | 135 | 9.2% | 9 | 38 |
| Product storage error | 133 | 9.0% | 0 | 0 |
| Metastatic malignant melanoma | 109 | 7.4% | 42 | 10 |
| Circumstance or information capable of leading to medication error | 89 | 6.0% | 0 | 0 |
| Death | 82 | 5.6% | 82 | 9 |
| Influenza like illness | 82 | 5.6% | 6 | 14 |
| Fatigue | 70 | 4.8% | 6 | 12 |
| Chills | 68 | 4.6% | 3 | 13 |
| Malignant melanoma | 64 | 4.3% | 15 | 9 |
| Therapy partial responder | 56 | 3.8% | 12 | 5 |
| Therapy non-responder | 50 | 3.4% | 8 | 3 |
| Injection site pain | 47 | 3.2% | 3 | 5 |
| Oral herpes | 47 | 3.2% | 1 | 0 |
| Nausea | 46 | 3.1% | 6 | 9 |
Other Indications for TALIMOGENE LAHERPAREPVEC
Malignant melanoma (562)
Product used for unknown indication (418)
Metastatic malignant melanoma (157)
Neuroendocrine carcinoma of the skin (37)
Melanoma recurrent (35)
Malignant melanoma stage iii (32)
Triple negative breast cancer (31)
Skin lesion (29)
Colorectal cancer (15)
Squamous cell carcinoma of skin (15)
Other Drugs Used for Off label use
LENALIDOMIDE (5,767)
ECULIZUMAB (3,550)
CERTOLIZUMAB PEGOL (2,256)
ABOBOTULINUMTOXINA (2,170)
LEVETIRACETAM (2,161)
APREMILAST (1,995)
PROPRANOLOL (1,576)
CETIRIZINE (1,416)
HUMAN IMMUNOGLOBULIN G (1,129)
THALIDOMIDE (1,033)